27439969|t|Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight / obese men
27439969|a|Gut microbial -derived short-chain fatty acids (SCFA) are believed to affect host metabolism and cardiometabolic risk factors. The present study aim was to investigate the effects of proximal and distal colonic infusions with the SCFA acetate on fat oxidation and other metabolic parameters in men. In this randomized, double-blind crossover trial, six overweight / obese men [body mass index (BMI) 25-35 kg/m(2)] underwent two experimental periods: one with distal and one with proximal colonic sodium acetate infusions. A feeding catheter was endoscopically positioned at the beginning of each period and remained in the colon for three consecutive test days, enabling colonic acetate (100 or 180 mmol/l) or placebo infusion during fasting conditions and after an oral glucose load (postprandial). Fat oxidation and energy expenditure were measured using an open-circuit ventilated hood system and blood samples were repeatedly collected for 2 h during fasting and postprandial conditions. Distal colonic 180 mmol/l acetate infusions increased fasting fat oxidation (1.78±0.28 compared with -0.78±0.89 g fat 2 h(-1), P=0.015), fasting peptide YY (PYY, P=0.01) and postprandial glucose and insulin concentrations (P<0.05), and tended to increase fasting plasma acetate (P=0.069) compared with placebo. Distal 100 mmol/l acetate administration tended to decrease fasting tumour necrosis factor-α (TNF-α; P=0.067) compared with placebo. In contrast, proximal colonic acetate infusions showed no effects on substrate metabolism, circulating hormones or inflammatory markers. In conclusion distal colonic acetate infusions affected whole-body substrate metabolism, with a pronounced increase in fasting fat oxidation and plasma PYY. Modulating colonic acetate may be a nutritional target to treat or prevent metabolic disorders.
27439969	0	6	Distal	T082	UMLS:C0205108
27439969	12	20	proximal	T082	UMLS:C0205107
27439969	22	29	colonic	T017	UMLS:C0009368
27439969	30	47	acetate infusions	T058	UMLS:C0574032
27439969	74	81	improve	T033	UMLS:C0184511
27439969	82	99	metabolic markers	T103	UMLS:C0578570
27439969	103	113	overweight	T033	UMLS:C0497406
27439969	116	121	obese	T038	UMLS:C0028754
27439969	122	125	men	T098	UMLS:C0025266
27439969	149	172	short-chain fatty acids	T103	UMLS:C0015691
27439969	174	178	SCFA	T103	UMLS:C0015691
27439969	208	218	metabolism	T038	UMLS:C0025519
27439969	223	251	cardiometabolic risk factors	T033	UMLS:C0035648
27439969	309	317	proximal	T082	UMLS:C0205107
27439969	322	328	distal	T082	UMLS:C0205108
27439969	329	336	colonic	T017	UMLS:C0009368
27439969	337	346	infusions	T058	UMLS:C0574032
27439969	356	368	SCFA acetate	T103	UMLS:C0015691
27439969	420	423	men	T098	UMLS:C0025266
27439969	433	443	randomized	T062	UMLS:C0034656
27439969	445	457	double-blind	T062	UMLS:C0013072
27439969	458	473	crossover trial	T062	UMLS:C0150097
27439969	479	489	overweight	T033	UMLS:C0497406
27439969	492	497	obese	T038	UMLS:C0028754
27439969	498	501	men	T098	UMLS:C0025266
27439969	503	518	body mass index	T201	UMLS:C1305855
27439969	520	523	BMI	T201	UMLS:C1305855
27439969	585	591	distal	T082	UMLS:C0205108
27439969	605	613	proximal	T082	UMLS:C0205107
27439969	614	621	colonic	T017	UMLS:C0009368
27439969	622	646	sodium acetate infusions	T058	UMLS:C2034525
27439969	650	666	feeding catheter	T074	UMLS:C2945625
27439969	671	685	endoscopically	T082	UMLS:C0442418
27439969	686	696	positioned	T082	UMLS:C0733755
27439969	749	754	colon	T017	UMLS:C0009368
27439969	797	804	colonic	T017	UMLS:C0009368
27439969	805	812	acetate	T058	UMLS:C0574032
27439969	836	843	placebo	T103	UMLS:C1696465
27439969	844	852	infusion	T058	UMLS:C0574032
27439969	860	867	fasting	T033	UMLS:C0015663
27439969	892	909	oral glucose load	T103	UMLS:C1955477
27439969	944	962	energy expenditure	T038	UMLS:C0014272
27439969	986	1021	open-circuit ventilated hood system	T074	UMLS:C0025080
27439969	1026	1039	blood samples	T031	UMLS:C0178913
27439969	1081	1088	fasting	T033	UMLS:C0015663
27439969	1118	1124	Distal	T082	UMLS:C0205108
27439969	1125	1132	colonic	T017	UMLS:C0009368
27439969	1144	1161	acetate infusions	T058	UMLS:C0574032
27439969	1172	1179	fasting	T033	UMLS:C0015663
27439969	1255	1262	fasting	T033	UMLS:C0015663
27439969	1263	1273	peptide YY	T103	UMLS:C0070358
27439969	1275	1278	PYY	T103	UMLS:C0070358
27439969	1305	1312	glucose	T103	UMLS:C0017725
27439969	1317	1324	insulin	T103	UMLS:C0021641
27439969	1373	1380	fasting	T033	UMLS:C0015663
27439969	1381	1387	plasma	T031	UMLS:C0032105
27439969	1388	1395	acetate	T103	UMLS:C0000975
27439969	1420	1427	placebo	T103	UMLS:C1696465
27439969	1429	1435	Distal	T082	UMLS:C0205108
27439969	1447	1469	acetate administration	T058	UMLS:C0574032
27439969	1489	1496	fasting	T033	UMLS:C0015663
27439969	1497	1521	tumour necrosis factor-α	T103	UMLS:C1456820
27439969	1523	1528	TNF-α	T103	UMLS:C1456820
27439969	1553	1560	placebo	T103	UMLS:C1696465
27439969	1575	1583	proximal	T082	UMLS:C0205107
27439969	1584	1591	colonic	T017	UMLS:C0009368
27439969	1592	1609	acetate infusions	T058	UMLS:C0574032
27439969	1641	1651	metabolism	T038	UMLS:C0025519
27439969	1665	1673	hormones	T103	UMLS:C0019932
27439969	1690	1697	markers	T201	UMLS:C0005516
27439969	1713	1719	distal	T082	UMLS:C0205108
27439969	1720	1727	colonic	T017	UMLS:C0009368
27439969	1728	1745	acetate infusions	T058	UMLS:C0574032
27439969	1755	1765	whole-body	T017	UMLS:C0444584
27439969	1776	1786	metabolism	T038	UMLS:C0025519
27439969	1818	1825	fasting	T033	UMLS:C0015663
27439969	1844	1850	plasma	T031	UMLS:C0032105
27439969	1851	1854	PYY	T103	UMLS:C0070358
27439969	1856	1866	Modulating	T082	UMLS:C0443264
27439969	1867	1874	colonic	T017	UMLS:C0009368
27439969	1875	1882	acetate	T103	UMLS:C0000975
27439969	1914	1919	treat	T058	UMLS:C0087111
27439969	1931	1950	metabolic disorders	T038	UMLS:C0025517